97 results
424B5
CRNX
Crinetics Pharmaceuticals, Inc.
21 Jun 24
Prospectus supplement for primary offering
6:11pm
of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled … by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting
S-3ASR
CRNX
Crinetics Pharmaceuticals, Inc.
21 Jun 24
Automatic shelf registration
4:45pm
, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing … to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals, Inc.
3 Jun 24
Regulation FD Disclosure
4:35pm
, with the majority of the effect in IGF-1 reductions observed between weeks two and four, and sustained throughout treatment.
Among those treated
S-3ASR
474cdlbg
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.2
qkx024n3viqbo6ko09
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
6x9oatm0
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
epxbfy6o9v2q4ip416yr
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
2eh8v6
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
00l1rn9yxyg7
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.2
6vaaiwd0och0fd
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
o0zdv hrar
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
424B5
fwj89tl3 n1mvp0
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
1axvl63biuwcarp
11 Sep 23
Prospectus supplement for primary offering
4:09pm